Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Just a heads up.

<< Previous

Bullboard Posts

Next >>

Comment by pabalooon Mar 03, 2021 5:22pm

103 Views

Post# 32710874

RE:RE:Just a heads up.

Maxie you sound angry. I better let you rest your losses must be astronomical. Another guy who put his life savings into a bad stock! Don't blame me for your lunacy I was just trying to help out future investors make informed decisions. I try to post facts that's it. Now go back in your mothers basement clown!

<< Previous

Bullboard Posts

Next >>

Nvidia reports record revenue in Q3